TRAMETINIB: 5,840 Adverse Event Reports & Safety Profile
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
5,840
Total FAERS Reports
938 (16.1%)
Deaths Reported
2,587
Hospitalizations
5,840
As Primary/Secondary Suspect
299
Life-Threatening
121
Disabilities
Prescription
Status
FDA Application: 217513 ·
First Report: 1991 · Latest Report: 20250801
What Are the Most Common TRAMETINIB Side Effects?
#1 Most Reported
Pyrexia
1,096 reports (18.8%)
#2 Most Reported
Malignant neoplasm progression
807 reports (13.8%)
#3 Most Reported
Product use in unapproved indication
349 reports (6.0%)
All TRAMETINIB Side Effects by Frequency
| Side Effect | Reports | % of Total | Deaths | Hosp. |
|---|---|---|---|---|
| Pyrexia | 1,096 | 18.8% | 113 | 640 |
| Malignant neoplasm progression | 807 | 13.8% | 320 | 205 |
| Product use in unapproved indication | 349 | 6.0% | 33 | 36 |
| Diarrhoea | 325 | 5.6% | 42 | 183 |
| Nausea | 301 | 5.2% | 67 | 172 |
| Rash | 290 | 5.0% | 25 | 96 |
| Vomiting | 289 | 5.0% | 59 | 187 |
| Fatigue | 269 | 4.6% | 39 | 127 |
| Death | 240 | 4.1% | 240 | 40 |
| Chills | 227 | 3.9% | 29 | 128 |
| Asthenia | 193 | 3.3% | 42 | 92 |
| Drug ineffective | 192 | 3.3% | 77 | 53 |
| Anaemia | 184 | 3.2% | 32 | 124 |
| Off label use | 176 | 3.0% | 37 | 38 |
| Metastatic malignant melanoma | 173 | 3.0% | 119 | 75 |
| Headache | 171 | 2.9% | 31 | 89 |
| Disease progression | 155 | 2.7% | 57 | 28 |
| Metastases to central nervous system | 155 | 2.7% | 83 | 56 |
| General physical health deterioration | 151 | 2.6% | 85 | 92 |
| Ejection fraction decreased | 150 | 2.6% | 11 | 50 |
Who Reports TRAMETINIB Side Effects? Age & Gender Data
Gender: 49.4% female, 50.6% male. Average age: 51.4 years. Most reports from: US. View detailed demographics →
Is TRAMETINIB Getting Safer? Reports by Year
| Year | Reports | Deaths | Hosp. |
|---|---|---|---|
| 2000 | 1 | 1 | 1 |
| 2010 | 3 | 1 | 2 |
| 2011 | 33 | 2 | 19 |
| 2012 | 40 | 2 | 16 |
| 2013 | 210 | 2 | 110 |
| 2014 | 469 | 40 | 301 |
| 2015 | 552 | 59 | 350 |
| 2016 | 359 | 85 | 258 |
| 2017 | 312 | 87 | 198 |
| 2018 | 485 | 66 | 317 |
| 2019 | 390 | 56 | 224 |
| 2020 | 285 | 48 | 153 |
| 2021 | 251 | 51 | 134 |
| 2022 | 230 | 39 | 121 |
| 2023 | 99 | 17 | 39 |
| 2024 | 93 | 12 | 39 |
| 2025 | 36 | 0 | 19 |
What Is TRAMETINIB Used For?
| Indication | Reports |
|---|---|
| Metastatic malignant melanoma | 1,604 |
| Malignant melanoma | 1,448 |
| Product used for unknown indication | 505 |
| Non-small cell lung cancer | 191 |
| Colorectal cancer | 158 |
| Glioma | 139 |
| Braf gene mutation | 94 |
| Neoplasm | 84 |
| Neoplasm malignant | 81 |
| Braf v600e mutation positive | 80 |
TRAMETINIB vs Alternatives: Which Is Safer?
TRAMETINIB vs TRAMETINIB DIMETHYL SULFOXIDE
TRAMETINIB vs TRANDOLAPRIL
TRAMETINIB vs TRANDOLAPRIL\VERAPAMIL
TRAMETINIB vs TRANEXAMIC ACID
TRAMETINIB vs TRANYLCYPROMINE
TRAMETINIB vs TRASTUZUMAB
TRAMETINIB vs TRASTUZUMAB-ANNS
TRAMETINIB vs TRASTUZUMAB DERUXTECAN
TRAMETINIB vs TRASTUZUMAB-DKST
TRAMETINIB vs TRASTUZUMAB-DTTB
Official FDA Label for TRAMETINIB
Official prescribing information from the FDA-approved drug label.